Skip to main content
Fig. 1 | BMC Neurology

Fig. 1

From: A mixed methodology, non-interventional study to evaluate the use of direct oral anticoagulants in UK clinical practice for patients with a first stroke associated with non-valvular atrial fibrillation: study protocol

Fig. 1

Study design and observation periods. Group 1: retrospective data collection for 300 eligible and consenting patients who present with first stroke associated with non-valvular atrial fibrillation (index event). The pre-index observation period is the 12-month period prior to the index event. The post-index observation period is the one month period following the index event Group 2: Prospective data collection for the first 150 eligible and consenting patients from Group 1 who commence treatment with apixaban (n = 50), edoxaban (n = 50), or rivaroxaban (n = 50). The post-DOAC observation period is from initiation of anti-FXa DOAC treatment up to a maximum of 7 months (6 months + 1 month window for completion of questionnaires) post-initiation. The baseline questionnaire will be completed within one month following anti-FXa DOAC initiation. The three-month questionnaire will be completed within the period beginning one week prior to and ending one month after the three-month post-initiation time point. The six-month questionnaire will be completed within the period beginning one week prior to and ending one month after the six-month post-initiation time point

Back to article page